Literature DB >> 22555466

Models for the study of Clostridium difficile infection.

Emma L Best1, Jane Freeman, Mark H Wilcox.   

Abstract

Models of Clostridium difficile infection (C. difficile) have been used extensively for Clostridium difficile (C. difficile) research. The hamster model of C. difficile infection has been most extensively employed for the study of C. difficile and this has been used in many different areas of research, including the induction of C. difficile, the testing of new treatments, population dynamics and characterization of virulence. Investigations using in vitro models for C. difficile introduced the concept of colonization resistance, evaluated the role of antibiotics in C. difficile development, explored population dynamics and have been useful in the evaluation of C. difficile treatments. Experiments using models have major advantages over clinical studies and have been indispensible in furthering C. difficile research. It is important for future study programs to carefully consider the approach to use and therefore be better placed to inform the design and interpretation of clinical studies.

Entities:  

Mesh:

Year:  2012        PMID: 22555466      PMCID: PMC3370947          DOI: 10.4161/gmic.19526

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  174 in total

1.  Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.

Authors:  Nicole J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Authors:  Thomas J Louie; Jennifer Peppe; C Kevin Watt; David Johnson; Rasheed Mohammed; Gordon Dow; Karl Weiss; Stuart Simon; Joseph F John; Gary Garber; Scott Chasan-Taber; David M Davidson
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

3.  Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.

Authors:  Chandrabali Ghose; Anuj Kalsy; Alaullah Sheikh; Julianne Rollenhagen; Manohar John; John Young; Sean M Rollins; Firdausi Qadri; Stephen B Calderwood; Ciaran P Kelly; Edward T Ryan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

4.  Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

Authors:  Simon D Baines; Katie Saxton; Jane Freeman; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2006-10-08       Impact factor: 5.790

5.  Adenosine deaminase inhibition prevents Clostridium difficile toxin A-induced enteritis in mice.

Authors:  Ana Flávia Torquato de Araújo Junqueira; Adriana Abalen Martins Dias; Mariana Lima Vale; Graziela Machado Gruner Turco Spilborghs; Aline Siqueira Bossa; Bruno Bezerra Lima; Alex Fiorini Carvalho; Richard Littleton Guerrant; Ronaldo Albuquerque Ribeiro; Gerly Anne Brito
Journal:  Infect Immun       Date:  2010-11-29       Impact factor: 3.441

6.  Experimental reproduction of neonatal diarrhea in young gnotobiotic hares simultaneously associated with Clostridium difficile and other Clostridium strains.

Authors:  J Dabard; F Dubos; L Martinet; R Ducluzeau
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

7.  The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives.

Authors:  Glen P Carter; Julian I Rood; Dena Lyras
Journal:  Gut Microbes       Date:  2010-01

8.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Authors:  David F Gardiner; Talia Rosenberg; Jerry Zaharatos; David Franco; David D Ho
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

10.  Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis.

Authors:  T A Bowden; A R Mansberger; L E Lykins
Journal:  Am Surg       Date:  1981-04       Impact factor: 0.688

View more
  51 in total

1.  A novel regulator controls Clostridium difficile sporulation, motility and toxin production.

Authors:  Adrianne N Edwards; Rita Tamayo; Shonna M McBride
Journal:  Mol Microbiol       Date:  2016-03-22       Impact factor: 3.501

2.  Toxin-positive Clostridium difficile latently infect mouse colonies and protect against highly pathogenic C. difficile.

Authors:  Lucie Etienne-Mesmin; Benoit Chassaing; Oluwaseyi Adekunle; Lisa M Mattei; Frederic D Bushman; Andrew T Gewirtz
Journal:  Gut       Date:  2017-02-20       Impact factor: 23.059

3.  Conserved oligopeptide permeases modulate sporulation initiation in Clostridium difficile.

Authors:  Adrianne N Edwards; Kathryn L Nawrocki; Shonna M McBride
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

Review 4.  Interactions Between the Gastrointestinal Microbiome and Clostridium difficile.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

5.  Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291.

Authors:  Jenessa A Winston; Rajani Thanissery; Stephanie A Montgomery; Casey M Theriot
Journal:  J Vis Exp       Date:  2016-12-10       Impact factor: 1.355

6.  Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection.

Authors:  France Mentré; Jean de Gunzburg; Charles Burdet; Sakina Sayah-Jeanne; Thu Thuy Nguyen; Perrine Hugon; Frédérique Sablier-Gallis; Nathalie Saint-Lu; Tanguy Corbel; Stéphanie Ferreira; Mark Pulse; William Weiss; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

7.  Mice with Inflammatory Bowel Disease are Susceptible to Clostridium difficile Infection With Severe Disease Outcomes.

Authors:  Fenfen Zhou; Therwa Hamza; Ashley S Fleur; Yongrong Zhang; Hua Yu; Kevin Chen; Jonathon E Heath; Ye Chen; Haihui Huang; Hanping Feng
Journal:  Inflamm Bowel Dis       Date:  2018-02-15       Impact factor: 5.325

Review 8.  Clostridium difficile infection.

Authors:  Wiep Klaas Smits; Dena Lyras; D Borden Lacy; Mark H Wilcox; Ed J Kuijper
Journal:  Nat Rev Dis Primers       Date:  2016-04-07       Impact factor: 52.329

Review 9.  Murine models to study Clostridium difficile infection and transmission.

Authors:  Trevor D Lawley; Vincent B Young
Journal:  Anaerobe       Date:  2013-09-25       Impact factor: 3.331

10.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Authors:  Kasper Krogh Andersen; Nika M Strokappe; Anna Hultberg; Kai Truusalu; Imbi Smidt; Raik-Hiio Mikelsaar; Marika Mikelsaar; Theo Verrips; Lennart Hammarström; Harold Marcotte
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.